Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series
Introduction: Immune Checkpoint Inhibitor (ICI) drugs have led to a revolution in the treatment of different forms of cancer, shifting the target of action from cancer cells to the patient’s immune system, enhancing their responses against the tumor itself. On the other hand, this mechanism can lead...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Applied Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-3417/12/24/12994 |
| _version_ | 1827641877409562624 |
|---|---|
| author | Daniele Pergolini Andrea Botticelli Roberta Fascetti Federica Rocchetti Alessio Cirillo Gianluca Tenore Gaspare Palaia Antonella Polimeni Umberto Romeo |
| author_facet | Daniele Pergolini Andrea Botticelli Roberta Fascetti Federica Rocchetti Alessio Cirillo Gianluca Tenore Gaspare Palaia Antonella Polimeni Umberto Romeo |
| author_sort | Daniele Pergolini |
| collection | DOAJ |
| description | Introduction: Immune Checkpoint Inhibitor (ICI) drugs have led to a revolution in the treatment of different forms of cancer, shifting the target of action from cancer cells to the patient’s immune system, enhancing their responses against the tumor itself. On the other hand, this mechanism can lead to responses against oneself, with the appearance of immune-related adverse events. The aim of the present study was to examine the immune-related adverse events (irAEs) affecting the mucous membranes of the oral cavity and the possible correlation between these and skin toxicities, which are reported in the literature as the most common adverse events. Materials and methods: Thirteen patients treated with anti-Programmed Death (PD-1) drugs (pembrolizumab, nivolumab, and cemiplimab) were selected. The data collected include the general history of the patient and the type of anticancer treatment. The sample was then analyzed by recording the alterations found on the mucous membranes of the oral cavity and on the skin. Finally, the average time that elapsed between the start of immunotherapy and the onset of lesions was analyzed. Results: Patients often had multiple lesions at the same time. Hyperkeratosis was found in three patients, candidiasis (pseudomembranous and median rhomboid glossitis) in two patients, epithelial atrophy in four patients, and ulcerative areas in two patients. One patient reported xerostomia with dysphagia. The anatomical areas most involved were the dorsal tongue and palate. Skin irAEs included skin rash erythema (<i>n</i> = 7) with diffuse redness, the presence of small bubbles with a crusty outcome, and dryness of the skin in the affected areas. Discussion: In the literature, there are few studies that analyze how irAEs affect the mucous membranes of the oral cavity in patients treated with ICI drugs. The most frequently described lesions are lichenoid reactions and xerostomia. Moreover, the development of mucositis, generally of low grade, has been reported. The present study has confirmed the data from the literature and, in addition, reports two cases of candidiasis, an adverse event that has never been shown in the literature. Conclusions: irAEs have the potential to affect any organ. The only way to avoid the occurrence of serious events that is currently available is early interception, which is only possible through the knowledge of these manifestations. It is therefore considered necessary to deepen our knowledge of oral irAEs and their correlation with dermatological toxicities, allowing for a multidisciplinary classification of the patient and a timely diagnosis of any adverse event and avoiding progression to more advanced stages, which could lead to the temporary or permanent suspension of anticancer drugs. |
| first_indexed | 2024-03-09T17:20:51Z |
| format | Article |
| id | doaj.art-23e7004a856d4f4f96f84fba6134faa0 |
| institution | Directory Open Access Journal |
| issn | 2076-3417 |
| language | English |
| last_indexed | 2024-03-09T17:20:51Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Applied Sciences |
| spelling | doaj.art-23e7004a856d4f4f96f84fba6134faa02023-11-24T13:08:19ZengMDPI AGApplied Sciences2076-34172022-12-0112241299410.3390/app122412994Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case SeriesDaniele Pergolini0Andrea Botticelli1Roberta Fascetti2Federica Rocchetti3Alessio Cirillo4Gianluca Tenore5Gaspare Palaia6Antonella Polimeni7Umberto Romeo8Department of Oral and Maxillofacial Sciences, Sapienza University of Rome, Via Caserta 6, 00161 Rome, ItalyDepartment of Radiological, Oncological and Anatomical-Pathological Sciences, Sapienza University of Rome, Viale Del Policlinico 155, 00161 Rome, ItalyDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Via Caserta 6, 00161 Rome, ItalyDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Via Caserta 6, 00161 Rome, ItalyDepartment of Radiological, Oncological and Anatomical-Pathological Sciences, Sapienza University of Rome, Viale Del Policlinico 155, 00161 Rome, ItalyDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Via Caserta 6, 00161 Rome, ItalyDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Via Caserta 6, 00161 Rome, ItalyDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Via Caserta 6, 00161 Rome, ItalyDepartment of Oral and Maxillofacial Sciences, Sapienza University of Rome, Via Caserta 6, 00161 Rome, ItalyIntroduction: Immune Checkpoint Inhibitor (ICI) drugs have led to a revolution in the treatment of different forms of cancer, shifting the target of action from cancer cells to the patient’s immune system, enhancing their responses against the tumor itself. On the other hand, this mechanism can lead to responses against oneself, with the appearance of immune-related adverse events. The aim of the present study was to examine the immune-related adverse events (irAEs) affecting the mucous membranes of the oral cavity and the possible correlation between these and skin toxicities, which are reported in the literature as the most common adverse events. Materials and methods: Thirteen patients treated with anti-Programmed Death (PD-1) drugs (pembrolizumab, nivolumab, and cemiplimab) were selected. The data collected include the general history of the patient and the type of anticancer treatment. The sample was then analyzed by recording the alterations found on the mucous membranes of the oral cavity and on the skin. Finally, the average time that elapsed between the start of immunotherapy and the onset of lesions was analyzed. Results: Patients often had multiple lesions at the same time. Hyperkeratosis was found in three patients, candidiasis (pseudomembranous and median rhomboid glossitis) in two patients, epithelial atrophy in four patients, and ulcerative areas in two patients. One patient reported xerostomia with dysphagia. The anatomical areas most involved were the dorsal tongue and palate. Skin irAEs included skin rash erythema (<i>n</i> = 7) with diffuse redness, the presence of small bubbles with a crusty outcome, and dryness of the skin in the affected areas. Discussion: In the literature, there are few studies that analyze how irAEs affect the mucous membranes of the oral cavity in patients treated with ICI drugs. The most frequently described lesions are lichenoid reactions and xerostomia. Moreover, the development of mucositis, generally of low grade, has been reported. The present study has confirmed the data from the literature and, in addition, reports two cases of candidiasis, an adverse event that has never been shown in the literature. Conclusions: irAEs have the potential to affect any organ. The only way to avoid the occurrence of serious events that is currently available is early interception, which is only possible through the knowledge of these manifestations. It is therefore considered necessary to deepen our knowledge of oral irAEs and their correlation with dermatological toxicities, allowing for a multidisciplinary classification of the patient and a timely diagnosis of any adverse event and avoiding progression to more advanced stages, which could lead to the temporary or permanent suspension of anticancer drugs.https://www.mdpi.com/2076-3417/12/24/12994cancer therapyimmunotherapyoral adverse eventsoral diseaseoral lesions |
| spellingShingle | Daniele Pergolini Andrea Botticelli Roberta Fascetti Federica Rocchetti Alessio Cirillo Gianluca Tenore Gaspare Palaia Antonella Polimeni Umberto Romeo Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series Applied Sciences cancer therapy immunotherapy oral adverse events oral disease oral lesions |
| title | Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series |
| title_full | Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series |
| title_fullStr | Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series |
| title_full_unstemmed | Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series |
| title_short | Oral Immune-Related Adverse Events Associated with PD-1 Inhibitor Treatment: A Case Series |
| title_sort | oral immune related adverse events associated with pd 1 inhibitor treatment a case series |
| topic | cancer therapy immunotherapy oral adverse events oral disease oral lesions |
| url | https://www.mdpi.com/2076-3417/12/24/12994 |
| work_keys_str_mv | AT danielepergolini oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries AT andreabotticelli oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries AT robertafascetti oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries AT federicarocchetti oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries AT alessiocirillo oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries AT gianlucatenore oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries AT gasparepalaia oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries AT antonellapolimeni oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries AT umbertoromeo oralimmunerelatedadverseeventsassociatedwithpd1inhibitortreatmentacaseseries |